Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Cystic Fibrosis Clinical Trials

A listing of Cystic Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (76) clinical trials

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

This is an observational, translational study examined bacterial morphology and function prevs. post antibiotic therapy in patients with CF who experience a pulmonary exacerbation that requires IV antibiotics. All clinical care is dictated by the treating physician(s). Inclusion criteria: Male or female with a confirmed diagnosis of CF (by sweat ...

Phase N/A

Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis

Numerous studies have demonstrated that patients with chronic illnesses are at increased risk for depression and anxiety. In large, well-controlled epidemiological studies, rates of depression in medical populations have ranged from 17% to 50% compared to 5% to 17.5% in healthy populations. Reporting on a community-based sample, Wells and colleagues ...

Phase N/A

Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor

Cystic Fibrosis related diabetes (CFRD), a major factor of morbid-mortality in CF, is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years. At the physiopathology level, insulin secretion is determinant in the glucose tolerance abnormalities in CF. Indeed insulin secretion is dependent of the ...

Phase N/A

Study of Mycobacterial Infections

The nontuberculous mycobacteria (NTM) are ubiquitous environmental organisms foundin soil and water that rarely cause disease in humans. Since exposure to these organisms is universal and disease is rare, it can be concluded that normal host defenses are almost always sufficient to prevent infection. It follows that otherwise healthy individuals ...

Phase N/A

Breath Condensate Study in Patients With Cystic Fibrosis.

We hypothesize that it is possible to recover microbial products causing infections in Exhaled Breath Condensate (EBC) samples as well as to measure markers of inflammation like Interleukin (IL)-8, Leukotriene B4 (LTB4), Interleukin IL-6, Interleukin IL-1B, Tumor Necrosis Factor alpha, as well as proteases like neutrophil elastase, matrix metalloproteinase 2 ...

Phase N/A

Natural History of Noncirrhotic Portal Hypertension

Noncirrhotic Portal Hypertension (NCPH) includes a spectrum of chronic liver diseases characterized by increased pressure within the portal circulation in the absence of cirrhosis. The complications from NCPH are similar to that of cirrhosis induced portal hypertension which includes the development of gastrointestinal varices, portal hypertensive gastropathy, splenomegaly, sepsis and ...

Phase N/A

Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases

Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited. Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire ...

Phase N/A

The Role of Bacteria and Genetic Variations in Cystic Fibrosis

Individuals with cystic fibrosis (CF) are susceptible to chronic bacterial colonization by Pseudomonas aeruginosa, which results in deterioration of lung function and, eventually, death. In this study, we hope to improve our understanding of the innate immune response to infection by strains of P. aeruginosa that express type III cytotoxins ...

Phase N/A

: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)

This study is a single center study of clinical and laboratory outcomes in patients 12 who transition from use of Orkambi to tez/iva. Clinical and laboratory measurements will be measured at baseline, 1 month, 3 months, and 6 months after initiation of tez/iva. The length of study participation will be ...

Phase N/A

Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis

Development of a multimodal questionnaire considering the FDA guidelines for patient reported outcome measures (PROM) Evaluation of reliability of the questionnaire by examining internal consistency and construct validity Evaluation of reproducibility of the questionnaire by re-testing of patients Assessment of cross-generational applicability of the questionnaire by sub-scoring of age groups ...

Phase N/A